[MO44] Mini-Oral Session 44　Lung Cancer / Thoracic Cancer 7（ICI）
【E】

[MO44-1] Pembrolizumab in advanced NSCLC patients with poor performance status and high PD-L1 expression: OLCSG 1801

^○Eiki Ichihara¹, Shinobu Hosokawa², Daijiro Harada³, Shoichi Kuyama⁴, Koji Inoue⁵, Kenichi Gemba⁶, Hirohisa Ichikawa⁷, Yuka Kato⁸, Naohiro Oda⁹, Isao Oze¹⁰, Tomoki Tamura⁴, Toshiyuki Kozuki³, Toshio Kubo¹¹, Akihiro Bessho², Katsuyuki Hotta⁸, Yoshinobu Maeda¹², Katsuyuki Kiura¹ (1.Department of Allergy and Respiratory Medicine, Okayama University Hospital, 2.Department of Respiratory Medicine, Japanese Red Cross Okayama Hospital, 3.Department of Thoracic Oncology, NHO Shikoku Cancer Center, 4.Department of Respiratory Medicine, NHO Iwakuni Clinical Center, 5.Department of Respiratory Medicine, Ehime Prefectural Central Hospital, 6.Department of Respiratory Medicine, Chugoku Central Hospital, 7.Department of Respiratory Medicine, KKR Takamatsu Hospital, 8.Center for Innovative Clinical Medicine, Okayama University Hospital, 9.Department of Respiratory Medicine, Fukuyama City Hospital, 10.Division of Cancer Epidemiology and Prevention, Department of Preventive Medicine, Aichi Cancer Center Research Institute, 11.Center for Clinical Oncology, Okayama University Hospital, 12.Department of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences)